Advaxis, Inc. 3 for 3 on Orphan Drug Requests - Siouxland News - KMEG 14 and FOX 44

Advaxis, Inc. 3 for 3 on Orphan Drug Requests

Posted: Updated:

PRINCETON, N.J. / ACCESSWIRE / May 5, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman’s Blog, written by the Company’s CEO, Mr. Daniel J. O’Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Mr. O’Connor reflects on the Company’s recently announced Orphan Drug Designation for ADXS-HPV for the treatment of Stage II-IV invasive cervical cancer. “The benefits of orphan status are considerable,” wrote Mr. O’Connor. Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/advaxis/daniel-oconnor/3-3-orphan-drug-requests).

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis’s immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

ADXS-HPV, Advaxis’s lead immunotherapy for the treatment of HPV-associated cancers, has demonstrated improved survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer. Advaxis is now planning the registrational program for ADXS-HPV. ADXS-HPV is also being evaluated in other HPV-associated cancers including a Phase 2 in advanced cervical cancer, a Phase 1/2 in head and neck cancer, and a Phase 1/2 in anal cancer. ADXS-HPV has orphan drug status for both anal and head and neck cancers. As part of its global commercialization strategy to enter into regional licensing deals with other market dominant biopharmaceutical companies in territories where there is a high prevalence of HPV-associated cancers, Advaxis has granted exclusive licenses for the development and commercialization of ADXS-HPV in Asia and India.

ADXS-cHER2 is an immunotherapy for the treatment of HER2 overexpressing cancers (such as breast, gastric, esophageal, and other cancers in humans and for osteosarcoma in canines). Advaxis’s lead animal-health immunotherapy, ADXS-cHER2, has demonstrated encouraging survival data in a Phase 1 trial in canine osteosarcoma. These data provide the rationale to advance this same immunotherapy into a Phase 1 clinical trial in women with HER2-positive breast cancer. The Company is preparing an IND submission for ADXS-cHER2 in breast cancer in 2014.

Advaxis has created more than 20 distinct immunotherapies based on its platform, either directly or through strategic collaborations with recognized cancer centers of excellence. We have clinical research collaborations with the University of Pennsylvania, Brown University, the Georgia Regents University Cancer Center, the Icahn School of Medicine at Mount Sinai, and others. For more information, visit http://www.advaxis.com/.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: Advaxis, Inc.   

ReleaseID: 415182

  • NewsNewsMore>>

  • Police Officer Charged with Drunk Driving

    Police Officer Charged with Drunk Driving

    (SIOUX CITY, IA) A Sioux City Police officer has been charged with drunk driving after allegedly causing a multi–car accident last month.More >>
    (SIOUX CITY, IA) A Sioux City Police officer has been charged with drunk driving after allegedly causing a multi–car accident last month.
    More >>
  • Hometown Farmer: Bob's Garden Perennials

    Hometown Farmer: Bob's Garden Perennials

    Everyone has a passion and for Bob Flick, it's flowers."You don't want to carry the flower in a small car." said Flick.Bob Flick is right. When this "Voodoo Lily" flowers it stinks Just ask the folks at the last garden show he took one to."They finally asked me to remove it because it stinks so bad, it's hilarious says Flick. Bob started working with plants at his grandpa's greenhouse when he was a kid. "Fifty cents an hour by the way, kids." And it turned into a real labor of love. Just look...More >>
    Everyone has a passion and for Bob Flick, it's flowers."You don't want to carry the flower in a small car." said Flick.Bob Flick is right. When this "Voodoo Lily" flowers it stinks Just ask the folks at the last garden show he took one to."They finally asked me to remove it because it stinks so bad, it's hilarious says Flick. Bob started working with plants at his grandpa's greenhouse when he was a kid. "Fifty cents an hour by the way, kids." And it turned into a real labor of love. Just look...More >>
  • A Man's Sanctuary Store

    A Man's Sanctuary Store

    When customers walk into the Man Cave Shop, they are hit by the buzz coming from the walls of neon. Store owner John Witkowski got into neon on a whim when he started the Floyd Boulevard business three months ago.More >>
    (SIOUX CITY, IA) When customers walk into the Man Cave Shop, they are hit by the buzz coming from the walls of neon. Store owner John Witkowski got into neon on a whim when he started the Floyd Boulevard business three months ago.More >>
Powered by WorldNow

Siouxland News
100 Gold Circle
Dakota Dunes, SD 57049

Main Phone: 712-277-3554
Main Fax: 712-255-5250
Email: webmaster@siouxlandnews.com

Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and Sinclair Communications, LLC. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.